The DAPA-HF trial, EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), and CANVAS (Canagliflozin Cardiovascular Assessment Study) confirmed that SGLT2- inhibitor treatment lowered rates of heart failure hospitalization (24–26). Here, SLC5A2 is linked to type 2 diabetes mellitus.